



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

Effective Date: 06/08/2023

Beovu® (brolocizumab-dblI)

HCPCS: J0179

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. FDA approved indication
 - b. FDA approved age
 - c. Treatment with bevacizumab or a bevacizumab biosimilar has been ineffective, not tolerated or contraindicated
 - d. Trial and failure, contraindication, OR intolerance to the preferred drugs as listed in BCBSM/BCN's utilization management medical drug list

- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: Align with FDA recommended dosing
 - b. Authorization Period: For at least 60 days and up to one year at a time
 - c. Renewal Criteria: Clinical documentation must be provided to confirm that current criteria are met and that the medication is providing clinical benefit

***Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Intravitreal injections of anti-vascular endothelial growth factor (VEGF) have been widely used by ophthalmologists to treat a variety of ocular diseases. They are injected directly into the eye to prevent the formation of new blood vessels and reduce blood vessel leakage and inflammation. Beovu is an anti-VEGF currently indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

- Age-related macular degeneration is a degenerative disease of the macula that results primarily in loss of central vision. Wet AMD is characterized by growth of abnormal vessels into the subretinal space. These abnormal blood vessels leak leading to collections of subretinal fluid and/or blood beneath the retina. The 2022 American Academy

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

of Ophthalmologists (AAO) Age-Related Macular Degeneration Preferred Practice Pattern Guidelines recommend observation and early detection, antioxidant vitamin and mineral supplements, and intravitreal injections of anti-VEGF agents for the management of wet AMD. Guidelines recommend Eylea™, Avastin®, Vabysmo™, or Lucentis® for treatment. The guidelines have not been updated with Beovu, Byooviz™, or Susvimo™.

References:

1. Beovu [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corp.; December 2022.
2. Avastin [prescribing information]. South San Francisco, CA: Genentech, Inc.; January 2021.
3. Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern. *Ophthalmology*. 2020 Jan (updated March 2022); 127 (1): P1 - P65.
4. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomized double masked study. *BMJ*. 2010; 340: c2459.
5. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. *Ophthalmology*. 2020 Jan; 127 (1): 72-84.
6. Vedula SS & Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. *The Cochrane database of systematic reviews*. 2008(2):CD005139. PMID: 18425911 6.
7. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. *The Cochrane database of systematic reviews*. 2019 Mar 4; 3: CD005139. PMID: 30834517.
8. Jhaveri CD, Glassman AR, Ferris FL, et al. Aflibercept monotherapy or bevacizumab first for diabetic macular edema. *NEJM*. 2022 Aug 25; 387: 692 – 703.

Policy History												
#	Date	Change Description										
1.4	Effective Date: 06/08/2023	Annual review of criteria was performed, no changes were made										
1.3	Effective Date: 04/06/2023	New policy. This policy replaces previously approved criteria that was embedded in the Intravitreal Injections for Retinal Conditions Policy which is being split into individual drug policies and retired. The authorization period for Beovu was updated from up to 1 year to at least 60 days and up to 1 year										
1.2	Effective Date: 02/03/2020	UM medical management system update for BCNA and MAPPO <table border="1" data-bbox="485 478 1365 686"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>Yes</td> </tr> <tr> <td>BCNA</td> <td>Yes</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	Yes											
BCNA	Yes											
1.1	Effective Date: 01/01/2020	UM medical management system update for BCBS <table border="1" data-bbox="485 758 1365 966"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	No											
BCNA	No											
1.0	Effective Date: 11/15/2019	UM medical management system update for BCN <table border="1" data-bbox="485 1037 1365 1245"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>No</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	Yes											
MAPPO	No											
BCNA	No											

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.